Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles

Veterinary Immunology and Immunopathology

Volumn 144, Issue 1-2, 2011, Pages 79-87

  Klier, John ^a   May, Anna ^a   Fuchs, Sebastian ^a   Schillinger, Ulrike ^b   Plank, Christian ^b   Winter, Gerhard ^a   Gehlen, Heidrun ^a,c   Coester, Conrad ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

BAL; CpG ODN; Gelatin nanoparticles; Horses; Immunotherapy; RAO

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GELATIN; GELATIN NANOPARTICLE; INTERLEUKIN 10; INTERLEUKIN 4; NANOPARTICLE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELIVERY SYSTEM; HORSE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LUNG ALVEOLUS CELL; LUNG LAVAGE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN MOTIF; RECURRENT DISEASE; TH1 CELL; TH2 CELL;

AIRWAY OBSTRUCTION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL SURVIVAL; CELLS, CULTURED; CPG ISLANDS; CYTOKINES; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GELATIN; HORSE DISEASES; HORSES; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; NANOPARTICLES;

EQUIDAE; MURINAE;

EID: 82555191056     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.07.009     Document Type: Article

References (43)

1. Ainsworth D.M., Grünig G., Matychak M.B., Young J., Wagner B., Erb H.N., Antczak D.F. Recurrent airway obstruction (RAO) in horses is characterized by IFN-g and IL-8 production in bronchoalveolar lavage cells. Vet. Immunol. Immunopathol. 2003, 96:83-91.
2. Ainsworth D.M. Just how important is IL 17 in horses with RAO?. 4th World Equine Airways Symposium (WEAS) 2009, 100-102. Pabst Science Publishers, Bern. C. Tessier, V. Gerber (Eds.).
3. Akdis M., Verhagen J., Taylor A., Karamloo F., Karagiannidis C., Crameri R., Thunberg S., Deniz G., Valenta R., Fiebig H., Kegel C., Disch R., Schmidt-Weber C.B., Blaser K., Akdis C.A. Immune Responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific t regulatory 1 and t helper 2 cells. J. Exp. Med. 2004, 199(11):1567-1575.
4. Bain F.T. Cytology of the respiratory tract. Vet. Clin. North Am. (Equine Pract) 1997, 13:477-486.
5. Bauer S., Kirschning C.J., Häcker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(16):9237-9242.
6. Bohle B. CpG motifs as possible adjuvants for the treatment of allergic diseases. Int. Arch. Allergy Immunol. 2002, 129:198-203.
7. Bourquin C., Anz D., Zwiorek K., Lanz A.-L., Fuchs S., Weigel S., Wurzenberger C., von der Borch P., Golic M., Moder S., Winter G., Coester, Endres S. Targeting CpG oligodeoxynucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol. 2008, 181:2990-2998.
8. Braun-Fahrländer C. Role of environment in asthma, endotoxin and other factors. 4th World Equine Airways Symposium (WEAS) 2009, 44-46. Pabst Science Publishers, Bern. C. Tessier, V. Gerber (Eds.).
9. Coester C., von Briesen H., Langer K., Kreuter J. Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake. J. Microencapsul. 2000, 17:187-193.
10. Cordeau M.E., Joubert P., Dewachi O., et al. IL-4, IL-5 and IFN-gamma mRNA expression in pulmonary lymphocytes in equine heaves. Vet. Immunol. Immunopathol. 2004, 97(1-2):87-96.
11. Debrue M., Hamilton E., Joubert P., Lajoie-Kadoch S., Lavoie J.P. Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells. Vet. Immunol. Immunopathol 2005, 105(1-2):25-31.
12. Fey K. Nichtinfektiöse Krankheiten der tiefen Atemwege und der Lunge. Handbuch der Pferdepraxis 2006, 326-332. Enke Verlag. third edition. O. Dietz, B. Huskamp (Eds.).
13. Fonseca D., Kline J. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Deliv. Rev. 2009, 61:256-262.
14. Gerber V., Straub R., Marti E., Hauptmann J., Herholz C., King M., Imhof A., Tahon L., Robinson N.E. Endoscopic scoring of mucus quantity and quality: observer and horse variance and relationship to inflammation, mucus viscoelasticity and volume. Equine Vet. J. 2004, 36:576-582.
15. Halliwell R.E.W., McGorum B.C., Irving P., Dixon P.M. Local and systemic antibody production in horses affected with chronic obstructive pulmonary disease. Vet. Immunol. Immunopathol. 1993, 38:201-215.
16. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 2000, 164:944-953.
17. Hartl D., Koller B., Mehlhorn A.T., Reinhardt D., Nicolai T., Schendel D.J., Griese M., Krauss-Etschmann S. Quantitative and functional impairment of pulmonary CD4+ CD25hi regulatory T cells in pediatric asthma. J. Allergy Clin. Immunol. 2007, 119:1258-1266.
18. Hawrylowicz C. Regulatory T cells in allergy and asthma: the role of the vitamin D pathway. 4th World Equine Airways Symposium (WEAS) 2009, 91-92. Pabst Science Publishers, Bern. C. Tessier, V. Gerber (Eds.).
19. Horohov D.W., Beadle R.E., Mouch S., Pourciau S.S. Temporal regulation of cytokine mRNA expression in equine recurrent airway obstruction. Vet. Immunol. Immunopathol. 2005, 108:237-245.
20. Horohov D.W., Mills W.R., Gluck M. Specific and innate immunity in the lung as it relates to equine RAO. 4th World Equine Airways Symposium (WEAS) 2009, 106-108. Pabst Science Publishers, Bern. C. Tessier, V. Gerber (Eds.).
21. Kline J.N., Krieg A.M. Oligodeoxynucleotides. New Drugs for Asthma, Allergy and COPD 2001, 31:229-232. Prog Respir Res, Basel, Karger.
22. Kline J.N. Immunotherapy of asthma using CpG Oligodeoxynucleotides. Immunol. Res. 2007, 39:279-286.
23. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
24. Krieg A.M. Therapeutic potential of toll-like receptor 9 activation. Nat. Rev. 2006, 5:471-484.
25. Lavoie J.P., Maghni K., Desnoyers M., Taha R., Martin J.G., Hamid Q.A. Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile. Am. J. Respir. Crit. Care Med. 2001, 164:1410-1413.
26. Liu T., Nerren J., Murrell J., Juillard V., El Garch H., Martens R., Cohen N. CpG-induced stimulation of cytokine expression by peripheral blood mononuclear cells of foals and their dams. JEVS 2008, 28(7):419-426.
27. Liu T., Nerren J., Liu M., Martens R., Cohen N. Basal and stimulus-induced cytokine expression is selectively impaired in peripheral blood mononuclear cells of newborn foals. Vaccine 2009, 27(5):674-683.
28. Marti E. Role of IgE and perspectives on clinical allergy testing. 4th World Equine Airways Symposium (WEAS) 2009, 109-111. Pabst Science Publishers, Bern. C. Tessier, V. Gerber (Eds.).
29. Millerick-May M. Quantification and control of environmental contaminants in stables. 4th World Equine Airways Symposium (WEAS) 2009, 192-194. Pabst Science Publishers, Bern. C. Tessier, V. Gerber (Eds.).
30. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y-J., Blazar B.R., Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD 25+ regulatory T cells. J. Immunol. 2004, 4433-4442.
31. Ólafsdóttir G., Svansson V., Torsteinsdóttir S. In vitro stimulation of horse peripheral blood mononuclear cells (PBMC) with adjuvant peptides and CpG motifs on a vector. International Symposium on Diseases of the Icelandic Horse, 2004 - Selfoss Iceland 2004, International Veterinary Information Service, Ithaca, NY, www.ivis.org. Icelandic Veterinary Association (Ed.).
32. Rankin R., Pontarollo R., Ioannou X., Krieg A.M., Hecker R., Babiuk L.A., van Drunen Little-van den Hurk S. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001, 11:333-340.
33. Robinson, N.E., 2001. Recurrent airway obstruction (Heaves). In: P. Lekeux (Ed.), Equine Respiratory Diseases, Document No. B0317.1101, Publisher: International Veterinary Information Service, Ithaca, New York. http://www.ivis.org/.
34. Schneberger D., Caldwell S., Singh Suri S., Singh B. Expression of toll-like receptor 9 in horse lungs. Anat. Rec. 2009, 292:1068-1077.
35. Schmallenbach K.H., Rahman I., Sasse H.H.L., Dixon P.M., Halliwell R.E.W., McGorum B.C., Crameri R., Miller H.R.P. Studies on pulmonary and systemic Aspergillus fumigatus-specific IgE and IgG antibodies in horses affected with chronic obstructive pulmonary disease (COPD). Vet. Immunol. Immunopathol. 1998, 66:245-256.
36. Senti G., Johansen P., Haug S., Bull C., Gottschaller C., Müller P., Pfister T., Maurer P., Bachmann M.F., Graf N., Kündig T.M. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy 2009, 39:562-570.
37. Stock P., Akbari O., Berry G., Freeman G., DeKruyff R., Umetsu D.T. Induction of TH1-like regulatory cells that express Foxp3 and protect against airway hyperreactivity. Nat. Immunol. 2004, 5:1149-1156.
38. Taylor A., Verhagen J., Blaser K., Akdis M., Akdis C.A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006, 117(4):433-442.
39. Umetsu D.T., DeKruyff R. The regulation of allergy and asthma. Immunol. Rev. 2006, 212:238-255.
40. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61(3):195-204.
41. van Scott M.R., Justice J.P., Bradfield J.F., Enright E., Sigounas A., Sur S. IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278:667-674.
42. Wilson K.D., de Jong S.D., Tam Y.K. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61(3):233-242.
43. Zwiorek K., Bourquin C., Battiany J., Winter G., Endres S., Hartmann G., Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 2008, 25(3):551-562.